PKD Educational Series
Join our renowned experts as they discuss and share their experience in autosomal dominant polycystic kidney disease (ADPKD) management in this learning series.
Themes & Objectives
- Discover the most common manifestations of ADPKD and the role of genetic testing
- Reflect on the past, present, and future of ADPKD management
- Identify patients with ADPKD for whom tolvaptan may be appropriate
- Recognize the role of V2 receptor signaling pathways
-
Jordan Weinstein
Associate Professor of Medicine,
University of Toronto
Nephrologist,
St. Michael’s Hospital
Founder & Director,
UKidney.com
Toronto, ON -
Daniel Bichet
Professor of Medecine, Pharmacology and Physiology,
l’Université de Montréal
Nephrologist, Hôpital du Sacré-Cœur de Montréal
Montréal, QC -
Arlene Chapman
Professor of Medicine, Department of Medicine,
Section Chief, Nephrology, Department of Medicine,
Director of Clinical Resource Center, University of Chicago
Chicago, IL, USA -
York Pei
Senior Scientist,
Toronto General Hospital Research Institute (TGHRI)
Professor of Medicine, University of Toronto
Nephrologist,
Toronto General Hospital, University Health Network
Toronto, ON -
Vicente E. Torres
Director,
Mayo Clinic Translational Polycystic Kidney Disease (PKD) Center
Consultant,
Division of Nephrology & Hypertension, Department of Internal Medicine
Rochester, MN, USA
